17.88
+7.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MiniMed Group, Inc. Common Stock
From its filings with the US Securities and Exchange Commission
MiniMed Group, Inc. Common Stock is based in Northridge, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MMED. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 24 April 2026, it reported revenue of $3.10bn and a net loss of $333.0m. At that date it held total assets of $4.63bn and shareholders' equity of $3.61bn.
We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes.
We were the first player in the market to commercialize all parts of an integrated diabetes management system. This allows us to provide a five-star customer experience: an easier and consistent user experience, seamless integration, privacy and security, optimized performance and reliability, and our pioneering and industry-leading dosing algorithm, based on TIR outcomes in real-world data. This differentiated value proposition is designed to solve two key problems for PWD. First, we believe our products deliver superior health outcomes, when measured against EASD and ADA guidelines, by effectively and measurably improving glycemic control compared to other available treatment options and competing products. By enhancing glycemic control, our products can help reduce long-term complications of diabetes, improve longevity and quality of life, and reduce associated costs to health systems. Second, our customer experience reduces or substantially eliminates the burden of diabetes management for users, their families, their caregivers, and their HCPs.
Quoted from its 10-K, filed 29 Jun 2026. Read the filing on SEC.gov ↗
Company facts
- Listed since
- 6 Mar 2026
- Employees
- 8,000
- Website
- minimed.com ↗
- Head office
- 18000 DEVONSHIRE ST., NORTHRIDGE, CA, 91325
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MiniMed Group's AID systems provide automated glucose sensing and insulin dosing for glycemic control.
- The company serves all T1D and a subset of T2D patients with insulin therapy needs.
- MiniMed Group offers InPen, Simplera, and Guardian 4 for Smart MDI systems and related services.
Weaknesses
- MiniMed Group has 8000 employees, which may indicate operational complexity.
- The company's focus on diabetes management limits diversification into other health sectors.
- Northridge, California, headquarters may restrict access to broader market opportunities.
Opportunities
- Expanding into T2D patient segments with insulin therapy requirements.
- Growing demand for continuous glucose monitors in the US healthcare market.
- Increasing adoption of AID systems for diabetes management globally.
Threats
- Competition from other medical technology firms in the US market.
- Regulatory changes affecting diabetes management devices in the US.
- Potential supply chain disruptions impacting insulin delivery devices production.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.